舒利迭TM与长效β_2受体激动剂治疗支气管哮喘的研究

Study of Soretide and Long-Effect β_2 Reactant Excitomotor Agent in Treating Bronchial Asthma

目的研究比较舒利迭TM与长效β2受体激动剂治疗支气管哮喘的临床疗效。方法采且双盲随机方法,治疗组即舒利迭TM每次1吸(50μg沙美特罗和100μg丙酸氟替卡松),每日2次;对照组给予福莫特罗干粉(商品名:奥克斯.都保)9μg吸入,每日2次。观察12周。结果治疗组肺功能、临床综合评分均有显著改善,统计资料显示两组差异具有非常显著性,P<0.01。结论舒利迭TM既有抗炎又有持续的支气管扩张作用。

[ Objective]To explore the clinical effect of Soretide and long- effect β2 reactant excitomotor agent in treating bronchial asthma. [Methods] Double- blind random approach was adopted; the administration group received Soretide inhalation twice per day （50 μg of Salmetero and 100 μg of Fluticasone every time） ; the control group received Fumotero powder inhalation twice per day （9 μg every time）. Observation was done for 12 weeks. [ Results] The lung function and the clinical synthesis grade of the administration group improved significantly, the difference was signifieant （ P 〈 0.01 ）. [ Conclusion] Soretide is effective for anti - inflammation and bronchus dilatation.